Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED).
About NTB003 Injection
NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development.
Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED.
Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604359716/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gogo Galileo HDX Connectivity Option Now Available on Cessna Citation CJ4 Gen312.8.2025 15:00:00 CEST | Press release
Customers who will be taking delivery of the Cessna Citation CJ4 Gen3 business jet now have the option to include the Gogo Galileo HDX connectivity solution installed on their aircraft. By integrating Gogo Galileo HDX, customers can benefit from an additional global connectivity solution that delivers exceptional performance. Announced in October 2024, the CJ4 Gen3 is expected to enter into service in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812553974/en/ Gogo Galileo HDX connectivity option now available on Cessna Citation CJ4 Gen3 (Photo Credit: Textron Aviation). The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are known for their luxury and productivity,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Whether for work or entertainment, this robust solution ensures customers’ in-flight exp
Unity Game Developers Can Now Enable Direct-to-Consumer Monetization With Xsolla’s New SDK12.8.2025 15:00:00 CEST | Press release
New Xsolla SDK for Unity Empowers Developers to Sell and Scale Games with Full Control of Their Revenue Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announces the launch of an SDK for Unity that expands monetization capabilities for developers using the Unity engine. This new SDK is a part of Xsolla’s continued mission to unlock direct-to-consumer revenue opportunities across all platforms - mobile, PC, and the web - without complex backend work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812923531/en/ (Graphic: Xsolla) Whether building a mobile-first title, a PC game, or a browser-based game, Unity developers can now integrate payments, enable in-game purchases, and create custom storefronts without relying on closed platforms. With a fast time-to-market, developers can start selling directly to their players and retain more of their revenue from day one, while ma
Pacific Avenue Capital Partners, a Leading Middle Market Private Equity Firm, Announces the Closing of More Than $1.65 Billion in Committed Capital12.8.2025 14:30:00 CEST | Press release
Pacific Avenue Capital Partners (“Pacific Avenue”), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced the closing of its second fund, Pacific Avenue Fund II, with more than $1.65 billion in committed capital. This includes a €100+ million sidecar vehicle that will be used alongside Fund II to pursue European opportunities. Fund II and the European sidecar were each raised in a single closing and completed in less than four months. The vehicles were significantly oversubscribed and received strong support from both new and existing investors. “We are incredibly grateful for the strong support and confidence shown by our existing and new investors,” said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue. “The overwhelmingly strong demand for Fund II and the European sidecar is a clear validation of our strategy.” Pacific Avenue strives to be the premier global partner for corporate carve-ou
Kinly Merges with Yorktel to Accelerate Global Growth and Expand Managed Services and Systems Integration Portfolios12.8.2025 14:00:00 CEST | Press release
Yorktel, a New Jersey-based global AV systems integrator and managed services provider, today announced it has signed an agreement to combine with Kinly, a global AV and UCC integration firm headquartered in Amsterdam, to merge the two firms into a premier workplace experience and collaboration provider with unparalleled reach. This strategic merger will significantly accelerate global growth and expand next-generation systems integration capabilities with a larger talent base and portfolio of managed services and technology offerings. The addition of Kinly’s operations, workforce, and client base will enhance Yorktel’s ability to meet the evolving needs of enterprise and public sector clients and provide a world-class customer experience across the globe. With complementary cultures and a shared commitment to service excellence, the planned integration strengthens Yorktel’s position as a trusted partner in digital workplace transformation while bringing additional capabilities and cap
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study12.8.2025 14:00:00 CEST | Press release
Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating the predictive utility of the MammaPrint 70-gene assay for chemotherapy benefit in patients with hormone receptor-positive, HER2-negative (HR+HER2-) early-stage breast cancer. The peer-reviewed article, titled "MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data," highlights how the MammaPrint Index predicts benefit from chemotherapy using a real-world, prospective, observational dataset. The findings are based on data from the ongoing FLEX Study (NCT03053193), a real-world data (RWD) study designed to collect whole transcriptome genomic data annotated with clinical data and outcomes from patients undergoing standard of care MammaPrint testing. This analysis included a propensity-score matched cohort of 1,002 patients with HR+HER2- breast cancer who received either chemotherapy wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom